Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

December 2017 Vol 3 No 6

Neratinib First Long-Term Adjuvant Therapy for Early-Stage, HER2-Positive Breast Cancer
On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab). Read More ›

Finding Empowerment Through a Multiple Myeloma Diagnosis
The majority of people diagnosed with multiple myeloma are age 60 or older; Ethan was only 22. Read about Ethan Hawes’ journey with multiple myeloma, which started with debilitating hip pain when he returned home from studying abroad. Read More ›

3 Questions to Ask When Being Diagnosed with Lung Cancer
Dr. Bruce Gershenhorn explores 3 questions patients should ask after learning they have lung cancer. Knowledge is power. Read More ›

Online Communities: Reaching Out to Others from the Comfort of Your Home
Online communities and message boards are terrific options for patients with cancer and survivors to connect and chat with experts and other patients. Take a look at the role online communities serve for survivors in today’s digital world. Read More ›

Blossoming Into Survivorship
“I have become an ally with fellow survivors, and have gained profound personal growth, which has ignited in me a passion to do the things I want to accomplish in life,” says Christine Magnus Moore, RN, BSN. Read More ›

Living with Uncertainty
Jason Micheli, a pastor and the author of Cancer is Funny: Keeping Faith in Stage-Serious Chemo, explains his mindset and the difficulties of dealing with uncertainty after a lymphoma diagnosis. Read More ›

Liver Cancer Cases Still Rising: Caregivers Feel Uninformed About Its Causes and Treatment Options
Unlike many types of cancers, the number of new cases of liver cancer, specifically hepatocellular carcinoma—the most common type of liver cancer—is increasing in the US. Read about the pressures, including the unmet needs, of caregivers of those affected by liver cancer. Read More ›

Gene Therapy a New Milestone in Immunotherapy
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer. Read More ›

The Dangers of Fake Medical News
In today’s busy news environment—with its 24-hour story cycles, social media platforms, and flood of information—phony medical news spreads like the flu. Read More ›

The Aftershocks Kept Coming: What to Expect After Cancer Treatment
Breast cancer survivor Lisa D’Ottavio describes the side effects of treatment that she experienced, from chemo hair loss, neuropathy, and lymphedema, to radiation effects and more. Read More ›

Page 2 of 3